GlobeNewswire by notified

Basilea reports on portfolio progress made in 2021

Share
  • Achieved important Cresemba® (isavuconazole) and Zevtera® (ceftobiprole) milestones
  • Added new clinical candidate BAL0891 to oncology pipeline and advanced clinical programs with derazantinib and lisavanbulin

Basel, January 06, 2022

Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with infectious diseases and cancer, provided today an update on the progress made with both its commercial brands and in its key research and development programs in 2021. The company achieved significant milestones and will continue to focus on delivering on its strategy for continued value creation in 2022.

David Veitch, Chief Executive Officer, commented: “Important milestones for our anti-infective brands included the marketing approval of Cresemba in China for the treatment for adult patients with invasive mucormycosis granted to our partner Pfizer and the filing of a marketing authorization application for isavuconazole in Japan by our partner Asahi Kasei Pharma. For Zevtera, we are expecting to complete patient enrolment into the phase 3 ERADICATE study this January. This will be an important milestone for a potential future U.S. market entry.” Topline results from the ERADICATE study are expected to become available around mid-year 2022.1

Significant progress has also been made in Basilea’s oncology pipeline, comprising the FGFR inhibitor derazantinib2, the tumor checkpoint controller lisavanbulin, as well as the mitotic checkpoint inhibitor BAL0891, which was recently added to the clinical portfolio.

Dr. Marc Engelhardt, Chief Medical Officer, said: “Derazantinib is our most advanced oncology drug candidate. The positive final results for FGFR2 fusion-positive bile duct cancer from the FIDES-01 study with derazantinib published in September 2021 underscored the favorable benefit to risk profile of derazantinib in this indication.”

Anti-infectives key highlights

  • In December 2021, Basilea’s partner Pfizer received a Drug Approval License for the oral formulation of Cresemba in China for the treatment of adult patients with invasive mucormycosis. This triggered a USD 10 million milestone payment to Basilea.
  • In September 2021, Basilea’s partner Asahi Kasei Pharma filed a New Drug Application (NDA) for the marketing authorization of isavuconazole in Japan for the treatment of the fungal infections: aspergillosis, mucormycosis and cryptococcosis. The filing is based on a phase 3 study completed in early 2021.3 It triggered a CHF 5 million milestone payment to Basilea. A decision on the NDA by the Japanese health authorities is expected in H2 2022.
  • In July 2021, Basilea entered into an agreement with Moscow-based pharmaceutical company JSC Lancet for the distribution of Zevtera in Russia, as well as in the other countries of the Eurasian Economic Union.
  • In May 2021, Basilea was awarded a grant of up to USD 2.7 million from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) for the development of selective inhibitors of the bacterial enzyme DXR. This enzyme is essential for the survival of many Gram-negative bacteria and has not yet been exploited as an antibacterial target.

The continued strong commercial performance of Cresemba throughout 2021 triggered several sales milestone payments by its partners to Basilea. By year-end 2021, Cresemba was approved in more than 60 countries and marketed in 55 countries, including the United States, most EU member states and additional countries inside and outside of Europe. In the twelve-month period between October 2020 and September 2021, total in-market sales of Cresemba amounted to more than USD 300 million, a 26.5 percent growth year-on-year.4

Oncology key highlights

  • In December 2021, the U.S. Food and Drug Administration (FDA) approved the Investigational New Drug (IND) application for starting clinical studies with the novel TTK/PLK1 kinase inhibitor BAL0891. The drug candidate is a first-in-class mitotic checkpoint inhibitor (MCI) that drives aberrant tumor cell division leading to tumor cell death. A phase 1 study in patients with advanced solid tumors is planned to start in the first quarter of 2022.
  • In September 2021, the full safety and efficacy data set from the first cohort of the phase 2 study FIDES-01 was presented at the ESMO congress. This cohort explored derazantinib as monotherapy in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma (iCCA).5 The data confirmed the efficacy of derazantinib and supported its differentiation in iCCA to other FGFR inhibitors related to safety and tolerability. Initial topline results from this cohort were reported in February 2021.
  • In July 2021, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to lisavanbulin for the treatment of malignant glioma, including glioblastoma. Orphan Drug Designation qualifies the sponsor of the drug for various incentives, including extended regulatory market exclusivity.
  • In March 2021, positive interim results from the second cohort of FIDES-01 were published. In this cohort, derazantinib is explored as monotherapy in iCCA patients with FGFR2 gene mutations and amplifications.
  • In February 2021, data on the safety, tolerability and preliminary signals of efficacy of derazantinib in combination with the PD-L1 checkpoint inhibitor atezolizumab in patients with advanced solid tumors from the phase 1b dose-finding cohort in the FIDES-02 study were presented at the ASCO Genitourinary Cancers Symposium. The derazantinib-atezolizumab combination was well tolerated and no dose-limiting toxicities were observed.

Multiple data readouts are expected throughout 2022 that will determine the direction for the further development of Basilea’s oncology drug candidates.

Topline derazantinib results for bile duct cancer (iCCA) patients with other FGFR2 genetic aberrations than fusions from the FIDES-01 study are expected in the first half of 2022 and Basilea also expects initial results from the ongoing urothelial and gastric cancer studies, FIDES-02 and FIDES-03, in the first half of 2022.6,7

Interim results from the ongoing lisavanbulin phase 2 study with EB1-positive glioblastoma patients are expected in the first half of 2022.8 EB1, end-binding protein 1, was previously identified as a potential response-predictive biomarker with long-lasting clinical benefit observed in two patients with recurrent EB1-positive glioblastoma, who participated in the program since the phase 1 portion of the study.

The second ongoing study with lisavanbulin is conducted in the U.S. in collaboration with the Adult Brain Tumor Consortium, ABTC, exploring the combination with radiotherapy in patients with newly diagnosed glioblastoma.9 Dose-escalation continues based on the combination's tolerability and safety profile observed so far. The maximum tolerated dose has not yet been reached and Basilea is now expecting the recommended phase 2 dose to be established in this patient population in the first half of 2022.

About Basilea

Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with cancer and infectious diseases. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. We are conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have several preclinical assets in both cancer and infectious diseases in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd. and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. Derazantinib and lisavanbulin and their uses are investigational and have not been approved by a regulatory authority for any use. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. The relevance of findings in nonclinical/preclinical studies to humans is currently being evaluated.

For further information, please contact:

Peer Nils Schröder, PhD

Head of Corporate Communications & Investor Relations
Phone +41 61 606 1102
E-mail media_relations@basilea.com
investor_relations@basilea.com

This press release can be downloaded from www.basilea.com.

References

  1. ERADICATE study: Clinicaltrials.gov identifier NCT03138733
    K. Hamed, M. Engelhardt, M. E. Jones et al. Ceftobiprole versus daptomycin in Staphylococcus aureus bacteremia: a novel protocol for a double-blind, Phase III trial. Future Microbiology. 2020 (1), 35-48
  2. Basilea in-licensed derazantinib from ArQule Inc., a wholly-owned subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A.
  3. Isavuconazole phase 3 study conducted by Asahi Kasei Pharma: Clinicaltrials.gov identifier NCT03471988
  4. IQVIA, September 2021. In-market sales reported as moving annual total (MAT) in U.S. dollar.
  5. FIDES-01 study: Clinicaltrials.gov identifier NCT03230318
  6. FIDES-02 study: Clinicaltrials.gov identifier NCT04045613
  7. FIDES-03 study: ClinicalTrials.gov identifier NCT04604132
  8. Biomarker-driven phase 2 study with lisavanbulin: ClinicalTrials.gov identifier NCT02490800
  9. Lisavanbulin phase 1 study conducted in collaboration with the ABTC: ClinicalTrials.gov identifier NCT03250299 

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Scandinavian Tobacco Group A/S: Transactions in connection with share buy-back programme17.1.2022 09:15:00 CET | Press release

Company Announcement No. 3/2022 Copenhagen, 17 January 2022 Transactions in connection with share buy-back programme On 10 March 2021, Scandinavian Tobacco Group A/S (“STG”) announced that a share buy-back programme of an aggregated price of up to DKK 600 million was launched with the purpose to adjust the Company’s capital structure and meet obligations relating to the Group’s share-based incentive programme. The buy-back programme is executed in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (the “Market Abuse Regulation”) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. The share buy-back programme will end no later than 28 February 2022. The following transactions have been executed from 10 January to 14 January 2022: Number of sharesAverage purchase price, DKKTransaction value, DKKAccumulated, last announcement4,015,833513,137,59110 January 202221,758137.472,990,98111 January 202214,980

Stolt-Nielsen Limited to Host a Video Conference to Present the Fourth Quarter and Full Year 2021 Results17.1.2022 09:00:00 CET | Press release

LONDON, January 17 , 2022 – Stolt-Nielsen Limited (Oslo Børs: SNI) will host a video conference to present the Company’s unaudited results for the fourth quarter and full year 2021 on Thursday, January 27, 2022 at 14:00 CET (08:00 EST, 13:00 GMT). The presentation and video conference will be hosted by: - Mr. Niels G. Stolt-Nielsen - Chief Executive Officer, Stolt-Nielsen Limited - Mr. Jens F. Grüner-Hegge - Chief Financial Officer, Stolt-Nielsen Limited - Mr. Lucas Vos - President, Stolt Tankers Those who wish to watch the live broadcast may access it here The presentation will be published on our website: https://www.stolt-nielsen.com/en/investors/reports-presentations/ For additional information please contact: Jens F. Grüner-Hegge Chief Financial Officer UK +44 (0) 20 7611 8985 j.gruner-hegge@stolt.com Ellie Davison Head of Corporate Communications UK +44 (0) 20 7611 8926 e.davison@stolt.com About Stolt-Nielsen Limited Stolt-Nielsen Limited (SNL or 'the Company') is a long-term inv

Jetex & Berlin Neuhardenberg Airport to Develop the World’s First Pure Green FBO in Berlin17.1.2022 08:30:49 CET | Press release

Dubai, United Arab Emirates, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Jetex, an award-winning global leader in executive aviation, and Berlin Neuhardenberg Airport announce the signing of a Joint Venture Agreement whereby both parties will work towards the development of a world-class executive aviation terminal and fixed base operation at Berlin Neuhardenberg Airport (EDON). Berlin is one of the top ten private aviation markets in Europe with more than 20,000 annual executive jet movements. “FBO Berlin Neuhardenberg” Special Purpose Vehicle (SPV) to be established in 50-50 joint venture shareholding partnership between Jetex and Berlin Neuhardenberg Airport. Jetex investment subject to certain conditions precedent being met by Berlin Neuhardenberg Airport. Private aviation aircraft operators and owners will benefit from a world-class dedicated FBO that will serve the Berlin, East Germany and Polish border market, offering the highest quality levels of hospitality, service, security and priva

Mika Salokangas appointed as a member of Telko Board of Directors17.1.2022 07:45:00 CET | Press release

Aspo Plc Stock Exchange Release January 17, 2022, at 8.45 a.m. Mika Salokangas appointedas a member of Telko Board of Directors Starting from February 1, 2022, Mika Salokangas, M. Sc. (Econ.), has been appointed to the Board of Directors of Telko Ltd, part of Aspo Group. Previously, Salokangas has served as Managing Director of Ahlsell Oy, as Vice President and in several management positions of Wihuri Oy and as the Managing Director of Agora Networks Oy and Oy Saab-Auto Ab. "I am very pleased that Mika Salokangas will start as a member of Telko's Board of Directors. His diverse background in demanding corporate management positions, and especially Mika's acquisition experience as Ahlsell’s Managing director for more than 10 years, fits well with Telko's compounder strategy," says Rolf Jansson, CEO of Aspo Group. Telko Ltd is an international leading expert in and supplier of plastic raw materials, industrial chemicals, and lubricants. Telko’s operations are based on representing the b

Sampo plc’s share buybacks 14/01/202217.1.2022 07:30:00 CET | Press release

SAMPO PLC STOCK EXCHANGE RELEASE 17/01/2022 at 08:30 am Sampo plc’s share buybacks 14/01/2022 On 14/01/2022 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows: Sampo plc’s share buybacksAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares*Market (MIC Code)17,15044.90AQEU21,65444.90CEUX3,47644.90TQEX88,05144.93XHELTOTAL130,33144.92 *rounded to two decimals On 1 October 2021, Sampo announced a share buyback programme of up to a maximum of EUR 750 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 4 October 2021, is based on the authorization granted by Sampo's Annual General Meeting on 19 May 2021. After the disclosed transactions, the company owns in total 9,776,009 Sampo A shares representing 1.76 per cent of the total number of shares in Sampo plc. Detail

Telenor Group agrees to sell its stake in Wave Money to Yoma Strategic17.1.2022 01:16:32 CET | Press release

(Singapore/Oslo, 17 January 2022) Telenor Group and Yoma Strategic have entered into an agreement to sell Telenor Group’s 51 percent share of Digital Money Myanmar Limited (“Wave Money”) for USD 53 million to Yoma MFS Holdings Pte. Ltd, a subsidiary of Yoma Strategic. This subsidiary is to be funded by a consortium of investors led by Yoma Strategic which remains subject to completion and final funding. When the transaction is concluded, Yoma Strategic will become the largest and controlling shareholder of Wave Money, ensuring that the company continue operations and further extend its leading role in Myanmar’s fintech sector. Wave Money is a leading provider of money transfer and digital payment solutions in Myanmar. The company was launched in November 2016 as a joint venture between Yoma Bank and Telenor Group, after the fintech pioneer was awarded a license to become the first non-bank institution to work under Myanmar's new Mobile Financial Services Regulation. In 2020, Wave Money

Telenor Group selger sin eierandel i Wave Money til Yoma Strategic17.1.2022 01:16:32 CET | Pressemelding

(Singapore/Oslo, 17. januar 2022) Telenor Group og Yoma Strategic har inngått en avtale om et salg av Telenors 51 prosents eierandel i Digital Money Myanmar Limited («Wave Money») for USD 53 millioner (rundt NOK 470 millioner) til Yoma MFS Holdings Pte. Ltd, et datterselskap av Yoma Strategic. Datterselskapet finansieres av et konsortium ledet av Yoma Strategic, og transaksjonen forutsetter endelig ferdigstillelse av denne finansieringen. Når salget er gjennomført vil Yoma Strategic bli den største og kontrollerende eier av Wave Money og sikre at selskapet fortsetter operasjonen og utvikler sin ledende rolle i Myanmars fintech sektor. Selskapet ble etablert i november 2016 som et joint venture mellom Yoma Bank og Telenor Group. Wave Money er en ledende leverandør av finansielle tjenester og digitale betalingsløsninger i Myanmar. Selskapet ble lansert i november 2016 som et fellesforetak mellom Yoma Bank og Telenor Group, etter at selskapet ble som første ikke-bankinstitusjon tildelt li